Ключевые слова
fluorobenzene; hydroxymethylglutaryl coenzyme A reductase inhibitor; pyrimidine derivative; rosuvastatin; sulfonamide; coronary artery disease; human; treatment outcome; Coronary Disease; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome